

PRIOR AUTHORIZATION POLICY

POLICY: Multiple Sclerosis – Fingolimod Prior Authorization Policy

- Gilenya® (fingolimod capsules – Novartis, generic)

REVIEW DATE: 10/09/2024

OVERVIEW

Fingolimod, a sphingosine 1-phosphate receptor modulator, is indicated for the treatment of patients with relapsing forms of **multiple sclerosis** (MS), to include clinically isolated syndrome, relapsing remitting disease, and active secondary progressive disease in patients ≥ 10 years of age.¹

Disease Overview

MS is a chronic, inflammatory, demyelinating, autoimmune disease of the central nervous system (CNS) that impacts almost 1,000,000 people in the US.²⁻⁴ The condition is marked by inflammation and demyelination, as well as degenerative alterations. Patients usually experience relapses and remissions in their neurological symptoms. For most patients, the onset of MS symptoms occurs when patients are 20 to 40 years of age; however, children can get MS and new onset disease can occur in older adults. The MS disease course is heterogeneous but has some patterns. Approximately 85% to 90% of patients have a relapsing pattern at onset. However, this transitions over time in patients who are untreated to a worsening with very few or no relapses or magnetic resonance imaging (MRI) activity (secondary progressive MS). Around 10% to 15% of patients have a steady progression of symptoms over time (primary progressive MS), marked by some clinical manifestations or by MRI activity. Primary progressive MS is generally diagnosed in patients on the upper level of the typical age range (e.g., almost 40 years of age) and the distribution is equivalent among the two genders. Advances in the understanding of the MS disease process, as well as in MRI technology, spurred updated disease course descriptions in 2013,⁵ as well as in 2017.⁶ The revised disease courses are clinically isolated syndrome, relapsing remitting MS, primary progressive MS, and secondary progressive MS.²⁻⁶ Clinically isolated syndrome is now more recognized among the course descriptions of MS. It is the first clinical presentation of MS that displays characteristics of inflammatory demyelination that may possibly be MS but has yet to fulfill diagnostic criteria. It is notable that the other MS designations can be further characterized considering whether patients have active disease (or not active), as well as if disease is worsening or stable. Disability in MS is commonly graded on the deterioration of mobility per the Expanded Disability Status Scale (EDSS) an ordinal scale that ranges from 0 to 10, with higher scores indicating greater disability.

Guidelines

In September 2019, a consensus paper was updated by the MS Coalition that discusses the use of disease-modifying therapies in MS.² Many options from various disease classes, involving different mechanisms of action and modes of administration, have shown benefits in patients with MS.² The American Academy of Neurology has practice guidelines regarding disease-modifying therapies for adults with MS.⁷ The guidelines cites fingolimod as one of the agents to consider for patients with MS who have highly active disease.

Safety

The initiation of fingolimod leads to decreases in heart rate.¹ After the first dose of fingolimod, the heart rate decreases are noted within an hour and generally are greatest at 6 hours, although the effects can be observed 24 hours after the first dose in some patients. The first dose of fingolimod should be given in a setting with resources to appropriately manage symptomatic bradycardia. Observe patients for 6 hours after

the first fingolimod dose for signs and symptoms of bradycardia. Patients with prolonged QTc interval at baseline or during the observation period, or taking medications with known risks of torsades de pointes, should be observed overnight with continuous electrocardiographic (ECG) monitoring. When restarting fingolimod after discontinuation for more than 14 days after the first treatment month, perform first-dose monitoring. There are several contraindications for use which mainly include patients with background cardiovascular disease. Fingolimod is associated with serious toxicities such as decreased heart rate and/or atrioventricular condition after the first dose; an increased risk of infections; macular edema; pulmonary toxicity; and elevated liver enzymes. Cases of progressive multifocal leukoencephalopathy (PML) have occurred in patients who were given fingolimod in the postmarketing setting.

POLICY STATEMENT

Prior Authorization is recommended for prescription benefit coverage of fingolimod. All approvals are provided for the duration noted below. Because of the specialized skills required for evaluation and diagnosis of patients treated with fingolimod as well as the monitoring required for adverse events and efficacy, approval requires fingolimod to be prescribed by or in consultation with a physician who specializes in the condition being treated.

Automation: None.

RECOMMENDED AUTHORIZATION CRITERIA

Coverage of fingolimod is recommended in those who meet the following criteria:

FDA-Approved Indication

1. Multiple Sclerosis. Approve for the duration noted below if the patient meets ONE of the following (A or B):

A) Initial Therapy. Approve for 1 year if the patient meets ALL of the following (i, ii and iii):

- i.** Patient has a relapsing form of multiple sclerosis; AND
Note: Examples of relapsing forms of multiple sclerosis include clinically isolated syndrome, relapsing remitting disease, and active secondary progressive disease.
- ii.** Patient is ≥ 10 years of age; AND
- iii.** Medication is prescribed by or in consultation with a neurologist or a physician who specializes in the treatment of multiple sclerosis; OR

B) Patient is Currently Receiving Fingolimod for ≥ 1 Year. Approve for 1 year if the patient meets ALL of the following (i, ii, iii and iv):

- i.** Patient has a relapsing form of multiple sclerosis; AND
Note: Examples of relapsing forms of multiple sclerosis include clinically isolated syndrome, relapsing remitting disease, and active secondary progressive disease.
- ii.** Patient is ≥ 10 years of age; AND
- iii.** Patient meets ONE of the following (a or b):
 - a)** Patient experienced a beneficial clinical response when assessed by at least one objective measure; OR
Note: Examples include stabilization or reduced worsening in disease activity as evaluated by magnetic resonance imaging (MRI) [absence or a decrease in gadolinium enhancing lesions, decrease in the number of new or enlarging T2 lesions]; stabilization or reduced worsening on the Expanded Disability State Scale (EDSS) score; achievement in criteria for No Evidence of Disease Activity-3 (NEDA-3) or NEDA-4; improvement on the fatigue

symptom and impact questionnaire-relapsing multiple sclerosis (FSIQ-RMS) scale; reduction or absence of relapses; improvement or maintenance on the six-minute walk test or 12-Item MS Walking Scale; improvement on the Multiple Sclerosis Functional Composite (MSFC) score; and/or attenuation of brain volume loss.

- b) Patient experienced stabilization, slowed progression, or improvement in at least one symptom such as motor function, fatigue, vision, bowel/bladder function, spasticity, walking/gait, or pain/numbness/tingling sensation; AND
- iv. Medication is prescribed by or in consultation with a neurologist or a physician who specializes in the treatment of multiple sclerosis.

CONDITIONS NOT RECOMMENDED FOR APPROVAL

Coverage of fingolimod is not recommended in the following situations:

1. **Concurrent Use with Other Disease-Modifying Agents Used for Multiple Sclerosis.** These agents are not indicated for use in combination (See [Appendix](#) for examples). Additional data are required to determine if use of disease-modifying multiple sclerosis agents in combination is safe and provides added efficacy.
2. **Non-Relapsing Forms of Multiple Sclerosis.** In the INFORMS trial, fingolimod did not slow disease progression in patients with primary progressive multiple sclerosis.⁸
Note: An example of a non-relapsing form of multiple sclerosis is primary progressive multiple sclerosis.
3. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

REFERENCES

1. Gilenya® capsules [prescribing information]. East Hanover, NJ: Novartis; June 2024.
2. A Consensus Paper by the Multiple Sclerosis Coalition. The use of disease-modifying therapies in multiple sclerosis. September 2019.
3. McGinley MP, Goldschmidt C, Rae-Grant AD. Diagnosis and treatment of multiple sclerosis. A review. *JAMA*. 2021;325(8):765-779.
4. No authors listed. Drugs for multiple sclerosis. *Med Lett Drugs Ther*. 2021;63(1620):42-48.
5. Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. *Neurology*. 2014;83:278-286.
6. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. *Lancet Neurol*. 2018;17(2):162-173.
7. Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis. Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. *Neurology*. 2018;90:777-788.
8. Lublin F, Miller DH, Freedman MS, et al, on behalf of the INFORMS Study Investigators. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomized, double-blind, placebo-controlled trial. *Lancet*. 2016;387:1075-1084.

APPENDIX